Sagimet Biosciences To Present Interim Data From Phase 2b Trial Of Denifanstat In NASH At EASL Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Sagimet Biosciences will present interim data from the FASCINATE-2 Phase 2b clinical trial of denifanstat, a fatty acid synthase inhibitor for nonalcoholic steatohepatitis (NASH), at the EASL Congress in Vienna, Austria on June 23, 2023.
June 07, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sagimet Biosciences' presentation of interim data from the FASCINATE-2 Phase 2b trial of denifanstat in NASH at EASL Congress 2023 may impact its stock price.
The presentation of interim data from the FASCINATE-2 Phase 2b trial of denifanstat in NASH at the EASL Congress 2023 is a significant event for Sagimet Biosciences. Positive results may lead to increased investor interest and a potential rise in the stock price, while negative results may have the opposite effect. The news is highly relevant and important for investors in SGMT, and the confidence in the analysis is based on the direct impact of the trial results on the company's prospects.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100